""
SYNTHESIS- Logo
A publication  of the UC Davis Cancer Center
""
Horizontal boundary
""
""
"" ""
  N E W S
"" ""
""
"" ""
""
"" ""
""
"" ""
"" Benefactors
"" ""
"" Featured Clinical Trial
"" ""
"" Calendar of Events
"" ""
"" News
""
"" ""
"" National Cancer Institute designation extended
"" Helping hands for kids with cancer
"" Just for new patients
  Koreans out-smoke other California men
  Longest survival rate for locally advanced lung cancer
  Chemotherapy after surgery boosts lung cancer survival
  Doris Matsui announces $6.5 million grant
"" ""
"" National Cancer Survivors Day celebrated
"" Ovarian cancer: Not so silent after all?
"" Ralph deVere White to lead Society of Urologic Oncology
  Smoking linked to two-thirds of cancer deaths in African American men
  Many say no to tamoxifen for breast-cancer prevention
  Cancer researcher honored
  Christine and Helen S. Landgraf Memorial Research Fund award recipients
"" ""
  Contact
"" ""
  Subscribe
"" ""
  Past issues
Vertical Seperator Line
 
Current Issue: Fall/Winter 2003
""
  NEWS
"" ""
""
"" ""
"" ""
 
""

Chemotherapy after surgery boosts lung cancer survival

Resolving a longstanding controversy in oncology, a study co-authored by David Gandara, associate director for clinical research at UC Davis Cancer Center, shows that administering chemotherapy after surgery improves survival for patients with early stage, resectable non-small cell lung cancer. The study appeared in the June 23, 2005 issue of The New England Journal of Medicine. The principal investigator was Timothy Winton of the National Cancer Institute of Canada Clinical Trials Group.

In the study, 482 patients with completely resected non-small cell lung cancer tumors were randomly assigned to observation or chemotherapy. The five-year, recurrence-free survival rate was 61 percent in the chemotherapy group, and 49 percent in the observation group. Cancer recurred in 87 patients in the chemotherapy group versus 119 in the observation group.

"We believe that a brief course of chemotherapy should become the standard of care after complete resection of Stage IB or Stage II nonsmall cell lung cancer," the authors concluded. An accompanying editorial in the journal agreed, stating: "The controversy surrounding adjuvant chemotherapy for resectable non-small lung cancer is over."

Non-small cell lung cancer is the most common form of lung cancer, accounting for 80 to 85 percent of all lung cancer cases.

 

""
"" ""
 
"" ""
"" ""
Vertical Seperator Line
"" "" ""
     
"" "" Vertical Seperator Line "" "" "" ""
"" "" Vertical Seperator Line
""
""

UC DAVIS CANCER CENTER
4501 X Street
Sacramento, CA 95817

cancer.center@ucdmc.ucdavis.edu

© 2006 UC Regents. All rights reserved.

"" "" ""